Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004906 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Hackensack Meridian Health.

Completed
Registry status
Phase 2
Development phase
4
Study locations

NCT00004906: Completed Phase 2 study of Breast Cancer, sponsored by Hackensack Meridian Health.

NCT00004906 is a Phase 2 study of Breast Cancer that has completed, run by Hackensack Meridian Health. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004906, a Phase 2 study of Breast Cancer, has completed, sponsored by Hackensack Meridian Health.

COMPLETED
Registry status
Phase 2
Development phase
4
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating women who have metastatic breast cancer.

Conditions Studied

Interventions

  • DRUG cisplatin
  • DRUG carboplatin
  • DRUG cyclophosphamide
  • DRUG anastrozole
  • BIOLOGICAL filgrastim

Study Locations (4)

Illinois

  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago

New Jersey

  • Hackensack University Medical Center - Hackensack

Ohio

  • Ireland Cancer Center - Cleveland

Pennsylvania

  • University of Pennsylvania Cancer Center - Philadelphia

Trial Details

FieldValue
Start Date 1999-10
Est. Completion 2001-06
Phase Phase 2

Sponsor

Hackensack Meridian Health

90 total trials

What the Registry Record Tells You About NCT00004906

The ClinicalTrials.gov registry entry for NCT00004906 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.

NCT00004906 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, New Jersey, Ohio.

Frequently Asked Questions

What is clinical trial NCT00004906 about?

NCT00004906 is a clinical study titled "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial...

What is the current status of trial NCT00004906?

This trial is currently completed. It is a Phase 2 study. The study started on 1999-10. Estimated completion is 2001-06.

What conditions does trial NCT00004906 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00004906?

The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), cyclophosphamide (DRUG), anastrozole (DRUG), filgrastim (BIOLOGICAL).

Who is sponsoring clinical trial NCT00004906?

This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004906 being conducted?

This trial has 4 study locations across Illinois, New Jersey, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.